EA202092931A1 - ANTITUMOR ANTAGONISTS OF IMMUNE CONTROL POINT REGULATORS - Google Patents

ANTITUMOR ANTAGONISTS OF IMMUNE CONTROL POINT REGULATORS

Info

Publication number
EA202092931A1
EA202092931A1 EA202092931A EA202092931A EA202092931A1 EA 202092931 A1 EA202092931 A1 EA 202092931A1 EA 202092931 A EA202092931 A EA 202092931A EA 202092931 A EA202092931 A EA 202092931A EA 202092931 A1 EA202092931 A1 EA 202092931A1
Authority
EA
Eurasian Patent Office
Prior art keywords
control point
antitumor antagonists
immune control
point regulators
antitumor
Prior art date
Application number
EA202092931A
Other languages
Russian (ru)
Inventor
Джеки З. Шэн
Бо ЛЮ
Маргарет Каров
Вэй Чжан
Хуэ Труонг
Original Assignee
Дженсан Биофарма, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженсан Биофарма, Инк. filed Critical Дженсан Биофарма, Инк.
Priority claimed from PCT/US2019/039994 external-priority patent/WO2020006516A1/en
Publication of EA202092931A1 publication Critical patent/EA202092931A1/en

Links

Abstract

Описаны противоопухолевые антагонисты, которые специфично связываются с регулятором иммунных контрольных точек. Также описан способ лечения пролиферативных расстройств с помощью противоопухолевых антагонистов.Antitumor antagonists have been described that specifically bind to an immune checkpoint regulator. Also described is a method of treating proliferative disorders using antitumor antagonists.

EA202092931A 2019-03-26 2019-06-28 ANTITUMOR ANTAGONISTS OF IMMUNE CONTROL POINT REGULATORS EA202092931A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962823989P 2019-03-26 2019-03-26
PCT/US2019/039994 WO2020006516A1 (en) 2018-06-29 2019-06-28 Antitumor immune checkpoint regulator antagonists

Publications (1)

Publication Number Publication Date
EA202092931A1 true EA202092931A1 (en) 2021-05-26

Family

ID=76160107

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092931A EA202092931A1 (en) 2019-03-26 2019-06-28 ANTITUMOR ANTAGONISTS OF IMMUNE CONTROL POINT REGULATORS

Country Status (1)

Country Link
EA (1) EA202092931A1 (en)

Similar Documents

Publication Publication Date Title
MX2022010229A (en) Composition for prophylaxis or treatment of il-8 related diseases.
MX2020012064A (en) Methods for treating atopic dermatitis by administering an il-4r inhibitor.
EA201892482A1 (en) COMPOUNDS MODULATING FXR (NR1H4)
MX2017003565A (en) Anti-age antibodies for treating inflammation and auto-immune disorders.
EA201790926A1 (en) COMBINED TREATMENT OF MALIGNANT NUMER FORMATION
BR112017017927A2 (en) chimeric anti-dll3 antigen receptors and methods of use
MX2017007390A (en) Use of immune checkpoint inhibitors in central nervous systems neoplasms.
MX2022001247A (en) Methods for treating atopic dermatitis by administering an il-4r antagonist.
EA201890185A1 (en) METHODS OF TREATMENT OF DISEASES MEDIATED BY GEPSID
MX2020009939A (en) Methods of treating prader-willi syndrome.
TN2019000161A1 (en) Anti-pd-1/anti-her2 natural antibody structure-like bispecific antibody of heterodimeric form and preparation thereof
TW201713333A (en) Methods of treating a neurodegenerative disease
MY184189A (en) Methods of treating nail and scalp psoriasis
EA202191086A1 (en) COMBINED MELANOMA THERAPY
MX2018009369A (en) Regulation of gene expression via aptamer-mediated control of self-cleaving ribozymes.
MX2019003235A (en) Methods for treating severe atopic dermatitis by administering an il-4r inhibitor.
MX2020011529A (en) A method for optimizing antibody expression.
EA201691426A1 (en) REGULATION OF ORNITIN METABOLISM TO CONTROL THE CONTENT OF HIGH-MANAGEMENT GLYFORMS OF RECOMBINANT PROTEIN
CY1125041T1 (en) ANTI-IL-22R ANTIBODIES
TR201903795T4 (en) NGS SYSTEMS CONTROL AND METHODS INCLUDING THIS
EA202191352A1 (en) CONTROL OF THE CONTENT OF MICROELEMENTS-METALS DURING THE PRODUCTION OF ANTIBODIES TO CD38
BR112022022800A2 (en) METHODS FOR TREATMENT OF MULTIPLE MYELOMA
EA201791970A1 (en) METHOD FOR TREATING PRIMARY SCLEROSED HOLANGITIS
BR112016029460A2 (en) Methods To Treat Rheumatoid Arthritis
EA202092931A1 (en) ANTITUMOR ANTAGONISTS OF IMMUNE CONTROL POINT REGULATORS